Inspire Medical Systems Faces Coding Overhang, Estimate Risks, BofA Says

MT Newswires Live05-22

Inspire Medical Systems (INSP) faces risks to estimates and the stock is unlikely to perform without consistent clarity on coding pathways for centers, BofA Securities said in a Friday research note.

The company's guidance assumes 2027 revenue will grow but it is difficult to predict a sustainable improvement until there is an official Category 1 code for the Inspire V leadless hypoglossal nerve stimulation system.

The brokerage lowered its 2027 EPS estimate to $1 from $1.15 and its revenue forecast to $854 million from $863 million earlier. The EPS estimate for 2028 was trimmed down to $1.28 from $1.35 and the revenue forecast was cut to $907 million from $917 million.

The company witnessed a decline in prior authorization submissions in Q1, but sees Q2 as the trough in growth, given early signs of PA volumes stabilizing and improving as centers gain coding experience, according to the note.

BofA downgraded the stock to underperform from neutral and cut its price target to $39 per share from $53.

Shares of Inspire Medical were down nearly 4% in Friday trading.

Price: 43.07, Change: -1.67, Percent Change: -3.73

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637348644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637348644","market":"sg","top_or_hot":-1,"title":"Inspire Medical Systems Faces Coding Overhang, Estimate Risks, BofA Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/INSP\">Inspire Medical Systems</a> (INSP) faces risks to estimates and the stock is unlikely to perform without consistent clarity on coding pathways for centers, BofA Securities said in a Friday research note.</p><p>The company's guidance assumes 2027 revenue will grow but it is difficult to predict a sustainable improvement until there is an official Category 1 code for the Inspire V leadless hypoglossal nerve stimulation system.</p><p>The brokerage lowered its 2027 EPS estimate to $1 from $1.15 and its revenue forecast to $854 million from $863 million earlier. The EPS estimate for 2028 was trimmed down to $1.28 from $1.35 and the revenue forecast was cut to $907 million from $917 million.</p><p>The company witnessed a decline in prior authorization submissions in Q1, but sees Q2 as the trough in growth, given early signs of PA volumes stabilizing and improving as centers gain coding experience, according to the note.</p><p>BofA downgraded the stock to underperform from neutral and cut its price target to $39 per share from $53.</p><p>Shares of Inspire Medical were down nearly 4% in Friday trading.</p><p>Price: 43.07, Change: -1.67, Percent Change: -3.73</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inspire Medical Systems Faces Coding Overhang, Estimate Risks, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInspire Medical Systems Faces Coding Overhang, Estimate Risks, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-22 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/INSP\">Inspire Medical Systems</a> (INSP) faces risks to estimates and the stock is unlikely to perform without consistent clarity on coding pathways for centers, BofA Securities said in a Friday research note.</p><p>The company's guidance assumes 2027 revenue will grow but it is difficult to predict a sustainable improvement until there is an official Category 1 code for the Inspire V leadless hypoglossal nerve stimulation system.</p><p>The brokerage lowered its 2027 EPS estimate to $1 from $1.15 and its revenue forecast to $854 million from $863 million earlier. The EPS estimate for 2028 was trimmed down to $1.28 from $1.35 and the revenue forecast was cut to $907 million from $917 million.</p><p>The company witnessed a decline in prior authorization submissions in Q1, but sees Q2 as the trough in growth, given early signs of PA volumes stabilizing and improving as centers gain coding experience, according to the note.</p><p>BofA downgraded the stock to underperform from neutral and cut its price target to $39 per share from $53.</p><p>Shares of Inspire Medical were down nearly 4% in Friday trading.</p><p>Price: 43.07, Change: -1.67, Percent Change: -3.73</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2637348644","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637348644","pubTimestamp":1779461176,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Inspire Medical Systems  faces risks to estimates and the stock is unlikely to perform without consistent clarity on coding pathways for centers, BofA Securities said in a Friday research note.The company's guidance assumes 2027 revenue will grow but it is difficult to predict a sustainable improvement until there is an official Category 1 code for the Inspire V leadless hypoglossal nerve stimulation system.The brokerage lowered its 2027 EPS estimate to $1 from $1.15 and its revenue forecast to $854 million from $863 million earlier. The EPS estimate for 2028 was trimmed down to $1.28 from $1.35 and the revenue forecast was cut to $907 million from $917 million.The company witnessed a decline in prior authorization submissions in Q1, but sees Q2 as the trough in growth, given early signs of PA volumes stabilizing and improving as centers gain coding experience, according to the note.BofA downgraded the stock to underperform from neutral and cut its price target to $39 per share from $5","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4082":"医疗保健设备","INSP":"Inspire Medical Systems"},"translate_title":"美国银行表示，Inspire Medical Systems面临编码过剩、估计风险","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSP":1.5},"content_text":"Inspire Medical Systems (INSP) faces risks to estimates and the stock is unlikely to perform without consistent clarity on coding pathways for centers, BofA Securities said in a Friday research note.The company's guidance assumes 2027 revenue will grow but it is difficult to predict a sustainable improvement until there is an official Category 1 code for the Inspire V leadless hypoglossal nerve stimulation system.The brokerage lowered its 2027 EPS estimate to $1 from $1.15 and its revenue forecast to $854 million from $863 million earlier. The EPS estimate for 2028 was trimmed down to $1.28 from $1.35 and the revenue forecast was cut to $907 million from $917 million.The company witnessed a decline in prior authorization submissions in Q1, but sees Q2 as the trough in growth, given early signs of PA volumes stabilizing and improving as centers gain coding experience, according to the note.BofA downgraded the stock to underperform from neutral and cut its price target to $39 per share from $53.Shares of Inspire Medical were down nearly 4% in Friday trading.Price: 43.07, Change: -1.67, Percent Change: -3.73","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637348644","isCrawlerRequest":true}